TransEnterix (NYSEMKT:TRXC) : The consensus on TransEnterix (NYSEMKT:TRXC) based on 5 analyst recommendation on the company stock is 1.6, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
TransEnterix (NYSEMKT:TRXC) : The highest short term price target forecast on TransEnterix (NYSEMKT:TRXC) is $4 and the lowest target price is $2. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $3.25 with a standard deviation of $0.79.
For the current week, the company shares have a recommendation consensus of Buy. Also, BTIG Research downgrades their rating on the shares of TransEnterix (NYSEMKT:TRXC). The current rating of the shares is Neutral. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on April 18, 2016.
TransEnterix (NYSEMKT:TRXC): stock turned positive on Tuesday. Though the stock opened at $1.08, the bulls momentum made the stock top out at $1.25 level for the day. The stock recorded a low of $1.075 and closed the trading day at $1.21, in the green by 10.00%. The total traded volume for the day was 913,883. The stock had closed at $1.1 in the previous days trading.
In an insider trading activity, Fernando Anthony C. J., officer (Chief Technology Officer) of Transenterix Inc., executed a transaction worth $39,420 on June 14, 2016. A total of 27,000 shares were purchased at an average price of $1.46. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
TransEnterix, Inc. is a medical device company focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot System (the SurgiBot System). The Companys SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon with robotic assistance while the surgeon remains patientside within the sterile field. It has commercialized the SPIDER Surgical System, (the SPIDER System) a manual laparoscopic system in the United States, Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels that are controlled directly by the surgeon, allowing for multiple instruments to be introduced through a single site. It also offers Flex Ligating Shears (FLS) which is an energy device used with the existing SPIDER Surgical System. The FLS device is designed to deliver controlled energy to ligate and divide tissue.